CClinicalTrials.gg
CompletedNCT03574623Updated Mar 20, 2026Results posted

Therapies for Recovery of Hand Function After Stroke

An interventional study of Electrical Stimulator and Occupational Therapy in Stroke, Upper Extremity Paresis and Hemiplegia, sponsored by MetroHealth Medical Center. Completed at 4 sites in United States. Open to participants aged 21 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by MetroHealth Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
21 Years to 90 Years
Sex
All
01

Study summary

After a stroke, it is very common to lose the ability to open the affected hand. The purpose of this study is to compare the effects of three different therapies on recovery of hand function after stroke and determine if any one is better than the other.

Read the detailed description

A single-blinded randomized controlled trial will be carried out to assess and compare the effects of 12 weeks of Contralaterally Controlled Functional Electrical Stimulation (CCFES), Cyclic Neuromuscular Electrical Stimulation (cNMES), and Task Oriented Training. Dexterity, upper limb impairment, and activity limitation will be assessed at 0 (baseline), 12 (end of treatment), and 36 weeks. The treatment dose will be the same for all three groups: 10 sessions per week of self-administered treatment at home plus 2 sessions per week of group-specific occupational therapy in the lab.

02

Conditions studied

  • Stroke
  • Upper Extremity Paresis
  • Hemiplegia

Keywords

  • stroke
  • rehabilitation
  • therapy
  • electrical stimulation
  • hand
03

In context

Stroke

7,286 studies on the registry are indexed under Stroke; 2,007 are open to participants now.

This study's enrollment of 132 is above the median of 50 across 5,369 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

MetroHealth Medical Center is the lead sponsor of 101 studies on the registry; 19 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 7 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 6 to 24 months since a first clinical cortical or subcortical, hemorrhagic or nonhemorrhagic stroke
  • unilateral upper limb hemiparesis with finger extensor strength of grade no more than 4 out of 5 on the Medical Research Council (MRC) scale
  • score of at least 1 and no more than 11 out of 14 on the hand section of the upper extremity Fugl-Meyer Assessment
  • adequate active movement of the shoulder and elbow to position the hand in the workspace for table-top task practice (necessary for the lab task practice sessions)
  • able to follow 3-stage commands
  • able to recall at least 2 of a list of 3 items after 30 minutes
  • skin intact on the hemiparetic arm
  • surface stimulation of the paretic finger and thumb extensors produces functional hand opening without pain (this will exclude those who have too much flexor spasticity)
  • able to hear and respond to cues from stimulator
  • not receiving occupational therapy (no concomitant OT)
  • full voluntary opening/closing of the contralateral (less affected) hand
  • demonstrates ability to follow instructions for operating the stimulator or have a caregiver who will assist them

Exclusion criteria

Exclusion Criteria:

  • co-existing neurologic diagnosis of peripheral nerve injury, Parkinson's disease, spinal cord injury, traumatic brain injury, or multiple sclerosis
  • uncontrolled seizure disorder
  • brainstem stroke
  • uncompensated hemineglect
  • severe shoulder or hand pain
  • insensate forearm or hand
  • history of potentially fatal cardiac arrhythmias with hemodynamic instability
  • implanted electronic systems (e.g. pacemaker)
  • botulinum toxin injections to any upper extremity muscle within 3 months of enrolling
  • pregnant women due to unknown risks of surface NMES during pregnancy
  • lack of functional passive range of motion of the wrist or fingers of affected side
  • diagnosis (apart from stroke) that substantially affects paretic arm and hand function
  • deficits in communication that interfere with reasonable study participation
  • lacking sufficient visual acuity to see the stimulator's display
  • concurrent enrollment in another investigational study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Experimental
    CCFES

    Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses an electrical stimulator and surface electrodes placed over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. Thus, volitional opening of the nonparetic hand produces stimulated opening of the paretic hand. During the lab visits, participants in the CCFES group will use CCFES to assist hand opening during occupational therapy task practice. During their home sessions, participants in the CCFES group will use CCFES to perform hand opening exercise.

    Device: Electrical Stimulator · Behavioral: Occupational Therapy

  • Active comparator
    cNMES

    Cyclic Neuromuscular Electrical Stimulation (cNMES) uses an electrical stimulator and surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation to open the weak hand. The stimulation automatically turns on and off causing the weak hand to open repetitively for several seconds at a time. During the lab visits, participants in the cNMES group will receive occupational therapy task practice. During their home sessions, participants in the cNMES group will use cNMES to perform hand opening exercise.

    Device: Electrical Stimulator · Behavioral: Occupational Therapy

  • Active comparator
    Task Oriented Therapy

    Task Oriented Therapy (TOT) focuses on practicing using the weak hand to practice activities of daily living tasks. During the clinic visits, participants in the TOT group will receive occupational therapy task practice. During their home sessions, participants in the TOT group will practice using their hand to complete a list of tasks given to them by the therapist to ensure that the participant receives a high dose of task practice.

    Behavioral: Occupational Therapy

Interventions

  • DeviceElectrical Stimulator

    An electrical stimulator will be used to deliver electrical current through surface electrodes to produce hand opening by making the paretic finger and thumb extensor muscles contract. The stimulator can be programmed to turn on and off in a repetitive cyclic fashion (i.e., cNMES) or be programmed to deliver stimulation with an intensity that corresponds to the opening of a glove instrumented with sensors and plugged into the stimulator (i.e., CCFES).

  • BehavioralOccupational Therapy

    Task practice that requires movement and use of the paretic hand under the guidance of a trained therapist.

06

What researchers measure

Primary outcomes

  1. Change in Box and Blocks Test (BBT) at 6 Months Post-Treatment

    The BBT is a measure of hand dexterity. It is a count of how many blocks a patient can pick up, move over a barrier, and release in 60 seconds. The higher the score, the better the motor recovery.

    Time frame: Baseline to 6 months post-treatment

Secondary outcomes

  1. Change in Upper Extremity Fugl Meyer (UEFM) at 6 Months Post-Treatment

    The UEFM is a measure of upper limb motor impairment with a minimum score of 0 and maximum score of 66. The higher the score, the better the motor recovery.

    Time frame: Baseline to 6 months post-treatment

  2. Change in Action Research Arm Test (ARAT) at 6 Months Post-Treatment

    The ARAT is a measure of arm and hand function with a minimum score of 0 and maximum score of 57. The higher the score, the better the motor recovery.

    Time frame: Baseline to 6 months post-treatment

  3. Change in Stroke Upper Limb Capacity Scale (SULCS) at 6 Months Post-Treatment

    The SULCS is a measure of upper limb capacity with a minimum score of 0 and maximum score of 10. The higher the score, the better the motor recovery.

    Time frame: Baseline to 6 months post-treatment

  4. Responder Rate

    Proportion of participants who had a gain of at least 6 points on the UEFM

    Time frame: Baseline to 6 months post-treatment

07

Results

Posted Mar 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneCCFEScNMESTask Oriented Therapy
Started444246
Completed363938
Not completed838

Outcome measures

PrimaryChange in Box and Blocks Test (BBT) at 6 Months Post-Treatment

The BBT is a measure of hand dexterity. It is a count of how many blocks a patient can pick up, move over a barrier, and release in 60 seconds. The higher the score, the better the motor recovery.

Time frame:
Baseline to 6 months post-treatment
Reported as:
Least squares mean · blocks
Change in Box and Blocks Test (BBT) at 6 Months Post-Treatment
blocksCCFEScNMESTask Oriented Training
Change in Box and Blocks Test (BBT) at 6 Months Post-Treatment5.1 (3.4 to 6.7)4.2 (2.6 to 5.8)3.0 (1.4 to 4.6)
SecondaryChange in Upper Extremity Fugl Meyer (UEFM) at 6 Months Post-Treatment

The UEFM is a measure of upper limb motor impairment with a minimum score of 0 and maximum score of 66. The higher the score, the better the motor recovery.

Time frame:
Baseline to 6 months post-treatment
Reported as:
Least squares mean · units on a scale
Change in Upper Extremity Fugl Meyer (UEFM) at 6 Months Post-Treatment
units on a scaleCCFEScNMESTask Oriented Training
Change in Upper Extremity Fugl Meyer (UEFM) at 6 Months Post-Treatment8.1 (6.1 to 10.1)3.7 (1.6 to 5.7)4.4 (2.4 to 6.4)
SecondaryChange in Action Research Arm Test (ARAT) at 6 Months Post-Treatment

The ARAT is a measure of arm and hand function with a minimum score of 0 and maximum score of 57. The higher the score, the better the motor recovery.

Time frame:
Baseline to 6 months post-treatment
Reported as:
Least squares mean · units on a scale
Change in Action Research Arm Test (ARAT) at 6 Months Post-Treatment
units on a scaleCCFEScNMESTask Oriented Training
Change in Action Research Arm Test (ARAT) at 6 Months Post-Treatment5.8 (3.6 to 7.9)4.8 (2.7 to 7.0)1.7 (-0.4 to 3.8)
SecondaryChange in Stroke Upper Limb Capacity Scale (SULCS) at 6 Months Post-Treatment

The SULCS is a measure of upper limb capacity with a minimum score of 0 and maximum score of 10. The higher the score, the better the motor recovery.

Time frame:
Baseline to 6 months post-treatment
Reported as:
Least squares mean · units on a scale
Change in Stroke Upper Limb Capacity Scale (SULCS) at 6 Months Post-Treatment
units on a scaleCCFEScNMESTask Oriented Training
Change in Stroke Upper Limb Capacity Scale (SULCS) at 6 Months Post-Treatment1.2 (0.7 to 1.7)0.8 (0.3 to 1.3)1.0 (0.5 to 1.5)
SecondaryResponder Rate

Proportion of participants who had a gain of at least 6 points on the UEFM

Time frame:
Baseline to 6 months post-treatment
Reported as:
Count of participants · Participants
Responder Rate
ParticipantsCCFEScNMESTask Oriented Training
Responder Rate221313

Adverse events

Collected over Enrollment to 6 months post-treatment. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CCFES0/44 (0%)0/44 (0%)5/44 (11.4%)
cNMES0/42 (0%)0/42 (0%)5/42 (11.9%)
Task Oriented Training0/46 (0%)0/46 (0%)0/46 (0%)
Most frequent other events
Most frequent other events
EventCCFEScNMESTask Oriented Training
Upper extremity pain possibly due to study-related increased use or overuseMusculoskeletal and connective tissue disorders3/445/420/46
Transient discomfort from electrical stimulationInvestigations1/442/420/46
Skin burn from stimulationInvestigations1/440/420/46

Baseline characteristics

Participants who completed the treatment

Age, Continuous
Age, Continuous(years)CCFEScNMESTask Oriented TrainingTotal
Mean58.7 ± 10.958.9 ± 13.760.6 ± 12.559.4 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)CCFEScNMESTask Oriented TrainingTotal
Female1317939
Male23222974
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CCFEScNMESTask Oriented TrainingTotal
African American58922
White23242370
Asian62311
Unknown or Chose Not To Answer2204
More than One Race0235
Native Hawaiian or Other Pacific Islander0101
Region of Enrollment
Region of Enrollment(participants)CCFEScNMESTask Oriented TrainingTotal
United States363938113
Time Since Stroke
Time Since Stroke(months)CCFEScNMESTask Oriented TrainingTotal
Mean12.4 ± 5.313.5 ± 5.113.5 ± 5.513.1 ± 5.3
Hand Weakness
Hand Weakness(Participants)CCFEScNMESTask Oriented TrainingTotal
Moderate18211958
Severe18181955
08

Study locations

4 sites
  • Emory University and Atlanta VA
    Atlanta, Georgia 30322, United States
  • Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Kessler Foundation
    West Orange, New Jersey 07052, United States
  • MetroHealth Rehabilitation Institute
    Cleveland, Ohio 44109, United States
09

References and documents

Publications

  • Knutson JS, Friedl AS, Hansen KM, Harley MY, Hogan SD, Cunningham DA, Hisel TZ, Plow EB, Barrett AM, Raghavan P, Boukrina O, Nahab F, Gunzler DD, Chae J. Contralaterally Controlled Functional Electrical Stimulation for Upper Extremity Recovery Following Stroke: A Multisite Randomized Controlled Trial. Stroke. 2026 Feb;57(2):338-348. doi: 10.1161/STROKEAHA.125.052891. Epub 2025 Nov 13. PubMed 41230603 ↗
  • Knutson JS, Friedl AS, Hansen KM, Harley MY, Barrett AM, Raghavan P, Plow EB, Gunzler DD, Chae J. Efficacy of contralaterally controlled functional electrical stimulation compared to cyclic neuromuscular electrical stimulation and task-oriented training for recovery of hand function after stroke: study protocol for a multi-site randomized controlled trial. Trials. 2022 May 12;23(1):397. doi: 10.1186/s13063-022-06303-y. PubMed 35549747 ↗

Study documents

  • Protocol and statistical analysis plan · Apr 19, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03574623
Lead sponsor
MetroHealth Medical Center
Collaborators
Kessler Foundation, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), The Cleveland Clinic, Johns Hopkins University, Emory University
Responsible party
Jayme Knutson (Senior Staff Scientist, MetroHealth Medical Center) — Principal investigator
First posted
Jul 2, 2018
Start date
Feb 15, 2019
Primary completion
Oct 16, 2024
Completion
Oct 16, 2024
Results posted
Mar 3, 2026
Last update
Mar 20, 2026

Study contacts

Jayme Knutson, PhD
principal investigator · MetroHealth Medical Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion